Avancerad sökning
Visar resultat 6 - 10 av 44 avhandlingar som matchar ovanstående sökkriterier.
6. Molecular Characterization of Bladder Cancer Subtypes
Sammanfattning : Bladder cancer is one of the most common malignancies world-wide, and in Sweden approximately 3000 cases are diagnosed annually. Even though bladder cancer is so common there is low public awareness of the disease, and it has historically been less studied compared to other common types of cancer. LÄS MER
7. Urinary Bladder Carcinoma – Studies of Outcome of Current Management and Experimental Therapy
Sammanfattning : The thesis concerns the epidemiology, current and possible future treatment of urothelial cancer of the urinary bladder. The Swedish National Quality Registry for Bladder Cancer 1997-2001 was used to explore epidemiology, current therapies and outcome. More common in men, the incidence for Ta and T1 tumours peaks in the age range 70-79 years. LÄS MER
8. Cancer Immunotherapy : A Preclinical Study of Urinary Bladder Cancer
Sammanfattning : Bacillus Calmette Guérin (BCG), or attenuated Mycobacterium bovis, is the gold standard of immunotherapy in the clinic to treat superficial bladder cancer. However, setbacks remain due to a high recurrence rate, side effects, and BCG-refractory disease. LÄS MER
9. Epigenetic and Phenotypic Profiling of Urothelial Carcinoma
Sammanfattning : Precise spatial and temporal regulation of gene expression programs is a prerequisite for multicellular life. Since the discovery of DNA as the carrier of genetic information, a key question in biology has been how these hard coded instructions are read and regulated to maintain cellular and organismal homeostasis. LÄS MER
10. Urinary bladder carcinoma, preclinical and clinical studies on EGFR based targeting
Sammanfattning : Radical cystectomy with bilateral pelvic lymphadenectomy is the standard treatment for muscle-invasive transitional cell carcinoma of the urinary bladder. Despite presumably localised malignancies and efficacious management about 50% of patients will die within 5 years, the majority due to metastatic disease. LÄS MER